PCLAF and Parkinson disease: Our findings of elevated levels of Lyso-PAF C-16, PC(44:6), PC(44:5) and depleted levels of PE(34:1), PC(35:6), ethanolamine, which also appears to be depleted in AD (Ellison et al., 1987) and three sphingomyelins in the plasma of our PD cohort support previous results about a perturbed glycerophospholipid and sphingolipid metabolism in PD (Ahmed et al., 2009; Kori et al., 2016) and underlines the potential of these parameters to serve as components of a biomarker panel in PD and to add to a better understanding of disease pathogenesis.